Intravacc - Broadly Protective Coronavirus Vaccine
- Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
- Total publications:1000 publications
Grant number: N/A
Grant search
Key facts
Disease
COVID-19start year
2022Known Financial Commitments (USD)
$4,800,000Funder
Coalition for Epidemic Preparedness Innovations (CEPI)Principal Investigator
N/A
Research Location
NetherlandsLead Research Institution
IntravaccResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Vaccine design and administration
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
October 6h, 2022; OSLO, Norway/Bilthoven, The Netherlands: CEPI, the Coalition for Epidemic Preparedness Innovations, and Dutch vaccine clinical development and manufacturing organization, Intravacc, today announced the latest funding award under CEPI's US$200m programme to advance the development of vaccines that provide broad protection against SARS-CoV-2 (including its variants) and other Betacoronaviruses. CEPI will provide seed funding of up to US$4.8 million to Intravacc'Äîa world leader in translational research and development of preventive and therapeutic vaccines'Äîto advance the development of a broadly protective Betacoronavirus vaccine candidate, which can be delivered intranasally. CEPI's funding will support preclinical development and testing of Intravacc's subunit vaccine candidate (Avacc 101), which is based on its Outer Membrane Vesicle (OMV) platform.
Publicationslinked via Europe PMC
Last Updated:2 days ago
View all publications at Europe PMC